Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) Insider Sells 1,342 Shares of Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) insider Andrea Difabio sold 1,342 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $55.23, for a total value of $74,118.66. Following the sale, the insider directly owned 7,301 shares in the company, valued at $403,234.23. The trade was a 15.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Andrea Difabio also recently made the following trade(s):

• On Tuesday, March 10th, Andrea Difabio sold 2,607 shares of Xenon Pharmaceuticals stock. The stock was sold at an average price of $60.11, for a total value of $156,706.77.

Xenon Pharmaceuticals Stock Performance

Shares of Xenon Pharmaceuticals stock traded down $2.67 on Friday, hitting $55.23. The stock had a trading volume of 3,849,961 shares, compared to its average volume of 1,923,723. The stock has a 50 day moving average of $43.71 and a 200 day moving average of $41.92. The firm has a market capitalization of $4.59 billion, a P/E ratio of -12.67 and a beta of 0.91. Xenon Pharmaceuticals Inc. has a twelve month low of $26.74 and a twelve month high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same period in the previous year, the company earned ($0.84) EPS. Equities analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Institutional Trading of Xenon Pharmaceuticals

A number of large investors have recently bought and sold shares of XENE. Avoro Capital Advisors LLC raised its position in shares of Xenon Pharmaceuticals by 0.5% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,424,444 shares of the biopharmaceutical company’s stock worth $243,124,000 after acquiring an additional 24,444 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Xenon Pharmaceuticals by 3.6% during the 4th quarter. Janus Henderson Group PLC now owns 4,084,034 shares of the biopharmaceutical company’s stock valued at $183,110,000 after purchasing an additional 140,149 shares in the last quarter. Wellington Management Group LLP grew its stake in Xenon Pharmaceuticals by 66.0% during the third quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock worth $144,936,000 after purchasing an additional 1,435,096 shares during the period. Braidwell LP grew its stake in Xenon Pharmaceuticals by 33.0% during the second quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company’s stock worth $112,837,000 after purchasing an additional 895,154 shares during the period. Finally, Capital International Investors increased its holdings in Xenon Pharmaceuticals by 7.3% in the fourth quarter. Capital International Investors now owns 3,414,959 shares of the biopharmaceutical company’s stock worth $153,058,000 after purchasing an additional 233,466 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Xenon Pharmaceuticals News Roundup

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase‑3 progress — Xenon completed the X‑TOLE2 Phase 3 study, placing XEN1101 (azetukalner) in focus for epilepsy investors and supporting a planned NDA timeline; this derisks the lead program and underpins longer‑term commercial value. Read More.
• Positive Sentiment: Big institutional interest — Reports note major funds increasing exposure (including a ~$200M position cited by The Motley Fool), which can add buying pressure into the stock on further positive catalysts. Read More.
• Positive Sentiment: Balance‑sheet boost — Xenon closed an upsized public offering that raised approximately $747.5M of gross proceeds, extending runway for Phase 3/commercial preparations and reducing near‑term financing risk. Read More.
• Positive Sentiment: Analyst upgrades — Several brokers raised price targets and reiterated Buy/Overweight ratings (Deutsche Bank, HC Wainwright, Wells Fargo and others), which can support short‑term demand. Read More.
• Neutral Sentiment: Model adjustments — HC Wainwright revised multi‑year EPS forecasts (improving FY2028–FY2030 assumptions but nudging FY2027), reflecting evolving commercialization timing; useful for context but subject to change. Read More.
• Neutral Sentiment: Volume and momentum — The stock has seen elevated trading volume following the analyst activity and trial news, which can amplify intraday moves in either direction. Read More.
• Negative Sentiment: Insider selling — CEO Ian Mortimer and several other insiders disclosed large open‑market sales (hundreds of thousands of shares by the CEO), reducing insider ownership and raising optics concerns for some investors. Read More.
• Negative Sentiment: Dilution risk — The sizable share issuance (and initial underwriter option) that funded the ~$747.5M raise increases outstanding shares and can pressure near‑term per‑share metrics despite improving cash runway. Read More.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on XENE shares. Bank of America reaffirmed a “buy” rating on shares of Xenon Pharmaceuticals in a research report on Monday. Wedbush increased their price target on Xenon Pharmaceuticals from $47.00 to $64.00 and gave the company an “outperform” rating in a research note on Tuesday. Morgan Stanley set a $97.00 price objective on Xenon Pharmaceuticals in a research report on Monday. Guggenheim reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Xenon Pharmaceuticals in a research note on Monday. Finally, JPMorgan Chase & Co. increased their target price on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research report on Friday, January 9th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $71.94.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.